# US 2002/0172675 A1 · Methods for detecting and inhibiting angiogenesis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2002/0172675 A1
- Document ID: US20020172675A1
- Status: Published application
- Kind: A1
- Application number: 10/190,460
- Filed: 2002-07-05
- Published: 2002-11-21
- Earliest claimed: 1998-05-08
- Assignees: The Regents of the University of California
- Inventors: Judith A. Varner
- Web page: https://patentgrep.com/patent/US20020172675A1

## CPC

- C07K 16/2842: {against integrin beta1-subunit-containing molecules, e.g. CD29, CD49}
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61P 35/00: Antineoplastic agents
- C07K 16/2845: {against integrin beta2-subunit-containing molecules, e.g. CD11, CD18}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides methods for reducing or inhibiting angiogenesis in a tissue, by contacting α5β1 integrin in the tissue with an agent that interferes with specific binding of the α5β1 integrin to a ligand expressed in the tissue; and methods of identifying angiogenesis in a tissue, by contacting the tissue with an agent that specifically binds α5β1 integrin, and detecting specific binding of the agent to α5β1 integrin associated with a blood vessel in the tissue. Also provided are methods of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual. The invention further provides methods of reducing or inhibiting angiogenesis in a tissue in an individual, by administering to the individual an agent that interferes with the specific binding of α5β1 integrin to a ligand expressed in the tissue; and methods of reducing the severity of a pathological condition associated with angiogenesis in an individual, by administering to the individual an agent that interferes with specific binding of α5β1 integrin to a ligand in a tissue associated with the pathological condition. The invention also provides methods of identifying an agent that reduces or inhibits angiogenesis associated with α5β1 integrin expression in a tissue by contacting a tissue exhibiting angiogenesis associated with α5β1 integrin expression with an agent, and detecting a reduction or inhibition of angiogenesis in the tissue.

## Claims

### Claim 1

A method of reducing or inhibiting angiogenesis in a tissue, comprising contacting α5β1 integrin in the tissue with an agent that interferes with specific binding of the α5β1 integrin to a ligand expressed in the tissue, thereby reducing or inhibiting angiogenesis in the tissue.

### Claim 2 (depends on 1)

The method of claim 1, wherein the agent does not substantially interfere with the specific binding of a ligand to an integrin other than α5β1 integrin to its ligand.

### Claim 3 (depends on 1)

The method of claim 1, wherein the ligand is fibronectin.

### Claim 4 (depends on 1)

The method of claim 1, wherein the tissue comprises ocular tissue.

### Claim 5 (depends on 4)

The method of claim 4, wherein the ocular tissue is selected from the group consisting of retina, macula and cornea.

### Claim 6 (depends on 1)

The method of claim 1, wherein the tissue comprises skin.

### Claim 7 (depends on 1)

The method of claim 1, wherein the tissue comprises synovial tissue.

### Claim 8 (depends on 1)

The method of claim 1, wherein the tissue comprises bone.

### Claim 9 (depends on 1)

The method of claim 1, wherein the tissue comprises a neoplasm.

### Claim 10 (depends on 9)

The method of claim 9, wherein the neoplasm is a malignant neoplasm.

### Claim 11 (depends on 10)

The method of claim 10, wherein the malignant neoplasm is a metastatic malignant neoplasm.

### Claim 12 (depends on 10)

The method of claim 10, wherein the malignant neoplasm is a carcinoma.

### Claim 13 (depends on 1)

The method of claim 1, wherein the agent comprises a peptide.

### Claim 14 (depends on 13)

The method of claim 13, wherein the peptide comprises the amino acid sequence CRRETAWAC (SEQ ID NO: 1).

### Claim 15 (depends on 1)

The method of claim 1, wherein the agent comprises an anti-α5β1 integrin antibody or an α5β1 integrin binding fragment of said antibody.

### Claim 16 (depends on 1)

The method of claim 1, wherein the agent comprises a nonpeptide organic molecule.

### Claim 17 (depends on 16)

The method of claim 16, wherein the nonpeptide organic molecule is a heterocycle having the general structure (S)-2-phenylsulfonylamino-3-55 {{8-(2-pyridinyl aminomethyl)-}-1-oxa-2-azaspiro-{4,5}-dec-2-en-yl}carbonylamino}propionic acid.

### Claim 18 (depends on 16)

The method of claim 16, wherein the nonpeptide organic molecule comprises (S)-2-{(2,4,6-trimethylphenyl)sulfonyl}amino-3-{7-benzyloxycarbonyl-8-(2-pyridinylaminomethyl)-1-oxy-2,7-diazaspiro-{4,4}-non-2-en-3-yl}carbonylamino}propionic acid.

### Claim 19 (depends on 1)

The method of claim 1, wherein the agent is linked to a cytotoxin.

### Claim 20 (depends on 19)

The method of claim 19, wherein the cytotoxin is a cancer chemotherapeutic drug.

### Claim 21

A method of identifying the presence of angiogenesis in a tissue, comprising the steps of:
a) contacting the tissue with an agent that specifically binds α5β1 integrin, and
b) detecting specific binding of the agent to α5β1 integrin associated with a blood vessel in the tissue, thereby identifying the presence of angiogenesis in the tissue.

### Claim 22 (depends on 21)

The method of claim 21, wherein the agent comprises a peptide.

### Claim 23 (depends on 21)

The method of claim 21, wherein the agent comprises the amino acid sequence CRRETAWAC (SEQ ID NO: 1).

### Claim 24 (depends on 21)

The method of claim 21, wherein the agent comprises an anti-α5β1 integrin antibody or an α5β1 integrin binding fragment of said antibody.

### Claim 25 (depends on 21)

The method of claim 21, wherein the agent comprises a nonpeptide organic molecule.

### Claim 26 (depends on 25)

The method of claim 25, wherein the nonpeptide organic molecule is a heterocycle having the general structure (S)-2-phenylsulfonylamino-3-{{{8-(2-pyridinyl aminomethyl)-}-1-oxa-2-azaspiro-{4,5}-dec-2-en-yl}carbonylamino}propionic acid.

### Claim 27 (depends on 25)

The method of claim 25, wherein the non-peptide organic molecule comprises (S)-2-{(2,4,6-trimethylphenyl)sulfonyl}amino-3-{7-benzyloxycarbonyl-8-(2-pyridinylaminomethyl) -1-oxy-2,7-diazaspiro-{4,4}-non-2-en-3-yl}carbonylamino}propionic acid.

### Claim 28 (depends on 21)

The method of claim 21, wherein the agent further comprises a detectable label.

### Claim 29 (depends on 21)

The method of claim 21, wherein detecting specific binding of the agent to α5β1 integrin associated with a blood vessel in the tissue comprises the steps of:
a) contacting the agent, which is specifically bound to α5β1 integrin, with a reagent that specifically interacts the agent, and
b) detecting interaction of the reagent, thereby detecting specific binding of the agent to α5β1 integrin associated with a blood vessel in the tissue.

### Claim 30 (depends on 21)

The method of claim 21, wherein the tissue is selected from the group consisting of embryonic tissue and placental tissue.

### Claim 31 (depends on 21)

The method of claim 21, wherein the tissue comprises granulation tissue.

### Claim 32 (depends on 21)

The method of claim 21, wherein the tissue is involved in a pathological condition.

### Claim 33 (depends on 32)

The method of claim 32, wherein the pathological condition comprises a neoplasm.

### Claim 34 (depends on 32)

The method of claim 32, wherein the tissue comprises ocular tissue.

### Claim 35

A method of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual, comprising the steps of:
a) obtaining a sample of the tissue from the individual, wherein, in an individual having the pathological condition, the tissue exhibits angiogenesis;
b) contacting the sample with an agent that specifically binds α5β1 integrin; and
c) detecting specific binding of the agent to α5β1 integrin associated with a blood vessel in the tissue, thereby diagnosing a pathological condition characterized by angiogenesis in the individual.

### Claim 36 (depends on 35)

The method of claim 35, wherein the pathological condition involves the eye.

### Claim 37 (depends on 36)

The method of claim 36, wherein the pathological condition is selected from the group consisting of diabetic retinopathy and macular degeneration by neovascularization.

### Claim 38 (depends on 35)

The method of claim 35, wherein the pathological condition involves the skin.

### Claim 39 (depends on 38)

The method of claim 38, wherein the pathological condition is selected from the group consisting of a hemangioma and psoriasis.

### Claim 40 (depends on 35)

The method of claim 35, wherein the pathological condition involves a joint.

### Claim 41 (depends on 40)

The method of claim 40, wherein the pathological condition is selected from the group consisting of rheumatoid arthritis and osteoarthritis.

### Claim 42 (depends on 33)

The method of claim 33, wherein the pathological condition involves a neoplasm.

### Claim 43 (depends on 42)

The method of claim 42, wherein the neoplasm is a malignant neoplasm.

### Claim 44 (depends on 43)

The method of claim 43, wherein the malignant neoplasm is a metastatic malignant neoplasm.

### Claim 45 (depends on 43)

The method of claim 43, wherein the malignant neoplasm is a carcinoma.

### Claim 46 (depends on 45)

The method of claim 45, wherein the carcinoma is 7 selected from the group consisting of breast carcinoma, colon carcinoma, ovarian carcinoma, and pancreatic carcinoma.

### Claim 47

A method of diagnosing a pathological condition characterized by angiogenesis in a tissue in an individual, comprising the steps of:
a) administering an agent that specifically binds α5β1 integrin to an individual suspected of having the pathological condition; and
b) detecting specific binding of the agent to α5β1 integrin associated with a blood vessel in the tissue, thereby diagnosing a pathological condition characterized by angiogenesis in the individual.

### Claim 48 (depends on 47)

The method of claim 47, wherein the agent is detectably labeled.

### Claim 49 (depends on 48)

The method of claim 48, wherein detecting specific binding of the agent is performed using an in vivo imaging method.

### Claim 50 (depends on 48)

The method of claim 48, wherein the detectably labeled agent comprises the agent linked to a label selected from the group consisting of a radionuclide, a paramagnetic material and an X-ray attenuating material.

### Claim 51 (depends on 49)

The method of claim 49, wherein the in vivo imaging method is selected from the group consisting of radionuclide imaging, positron emission tomography, computerized axial tomography, and magnetic resonance imaging.

### Claim 52 (depends on 48)

The method of claim 48, wherein detecting specific binding of the agent to α5β1 integrin associated with a blood vessel in the tissue comprises the steps of:
a) obtaining a sample of the tissue from the individual; and
b) detecting specific binding of the agent in the sample.

### Claim 53 (depends on 47)

The method of claim 47, wherein detecting specific binding of the agent to α5β1 integrin associated with a blood vessel in the tissue comprises the steps of:
a) obtaining a sample of the tissue from the individual;
b) contacting the agent that is specifically bound to α5β1 integrin with a reagent that specifically interacts with the agent; and
c) detecting interaction of the reagent with the agent, thereby diagnosing a pathological condition characterized by angiogenesis in the individual.

### Claim 54 (depends on 47)

The method of claim 47, wherein the individual is a human.

### Claim 55

A method of reducing or inhibiting angiogenesis in a tissue in an individual, comprising administering to the individual an agent that interferes with the specific binding of α5β1 integrin to a ligand expressed in the tissue, thereby reducing or inhibiting angiogenesis in the tissue in the individual.

### Claim 56 (depends on 55)

The method of claim 55, wherein the individual is a human.

### Claim 57

A method of reducing the severity of a pathological condition associated with angiogenesis in an individual, comprising administering to the individual an agent that interferes with specific binding of α5β1 integrin to a ligand in a tissue associated with the pathological condition, thereby reducing or inhibiting angiogenesis in the tissue, and reducing the severity of the pathological condition.

### Claim 58 (depends on 57)

The method of claim 57, wherein the pathological condition is a neoplasm.

### Claim 59 (depends on 58)

The method of claim 58, wherein the neoplasm is a malignant neoplasm.

### Claim 60 (depends on 59)

The method of claim 59, wherein the malignant neoplasm is a metastatic malignant neoplasm.

### Claim 61 (depends on 59)

The method of claim 59, wherein the malignant neoplasm is a carcinoma.

### Claim 62 (depends on 61)

The method of claim 61, wherein the carcinoma is selected from the group consisting of a breast carcinoma, a colon carcinoma, an ovarian carcinoma and a pancreatic carcinoma.

### Claim 63 (depends on 59)

The method of claim 59, wherein the malignant neoplasm is selected from the group consisting of a sarcoma, a mesothelioma, a teratocarcinoma, an astrocytoma, and a glioblastoma.

### Claim 64 (depends on 57)

The method of claim 57, wherein the individual is a human.

### Claim 65 (depends on 57)

The method of claim 57, wherein the agent is administered intravenously.

### Claim 66 (depends on 57)

The method of claim 57, wherein the agent is administered orally.

### Claim 67 (depends on 58)

The method of claim 58, wherein the agent is administered into a neoplasm.

### Claim 68 (depends on 57)

The method of claim 57, wherein the pathological condition is associated with the eye.

### Claim 69 (depends on 68)

The method of claim 68, wherein the pathological condition is selected from the group consisting of diabetic retinopathy and macular degeneration by neovascularization.

### Claim 70 (depends on 68)

The method of claim 68, wherein the agent is administered in the form of eye drops.

### Claim 71 (depends on 68)

The method of claim 68, wherein the agent is administered intravenously.

### Claim 72 (depends on 68)

The method of claim 68, wherein the agent is administered orally.

### Claim 73 (depends on 57)

The method of claim 57, wherein the pathological condition is associated with a joint.

### Claim 74 (depends on 73)

The method of claim 73, wherein the agent is administered intrasynovially.

### Claim 75 (depends on 57)

The method of claim 57, wherein the agent is administered at a dose of 0.0001 to 100 mg/kg body weight.

### Claim 76

A method of identifying an agent that reduces or inhibits angiogenesis associated with α5β1 integrin expression in a tissue, comprising the steps of:
a) contacting a tissue exhibiting angiogenesis associated with α5β1 integrin expression with an agent; and
b) detecting a reduction or inhibition of angiogenesis in the tissue, thereby identifying an agent that reduces or inhibits angiogenesis associated with α5β1 integrin expression in a tissue.

### Claim 77 (depends on 76)

The method of claim 76, wherein contacting the tissue occurs in vivo.

### Claim 78 (depends on 76)

The method of claim 76, wherein contacting the tissue occurs ex vivo.

### Claim 79 (depends on 76)

The method of claim 76, wherein the tissue comprises malignant neoplastic tissue.
